
Strides Pharma Science Ltd announced that its subsidiary, Strides Pharma Global Pte Ltd in Singapore, has secured approval from the US Food & Drug Administration (USFDA) for its generic Sevelamer Carbonate for oral suspension. This medication is designed for patients with chronic kidney disease undergoing dialysis to prevent dangerous phosphate level increases. Strides Pharma Science revealed that the approval covers Sevelamer Carbonate for oral suspension with strengths of 0.8g and 2.4g, making it bioequivalent and therapeutically equivalent to the reference listed drug Renvela for Oral Suspension by Genzyme. This approval significantly enhances Strides' Sevelamer Carbonate portfolio, marking a significant milestone.
Like
Save
Share